Reading the REDEFINE results: what CagriSema did and did not prove

TL;DR

• CagriSema combines cagrilintide, an amylin-receptor agonist, and semaglutide, a GLP-1-receptor agonist.¹
• In REDEFINE 1, average weight changed by -20.4% with CagriSema versus -3.0% with placebo at 68 weeks.²
• Gastrointestinal events were common: 79.6% with the combination and 39.9% with placebo, mostly mild to moderate and temporary.³
• The group-level result was large, but indirect rankings cannot replace direct comparisons across different studies, groups, locations, follow-up periods, and research questions or predict one reader’s result accurately in advance.⁴

For Filipino readers, a dramatic headline number can feel like the whole story. It is not. REDEFINE 1 deserves attention because it was large, randomized, controlled, and followed participants for 68 weeks.⁵ Reading it well means separating what happened inside that trial from what remains unanswered outside it, including longer-term outcomes and locally representative evidence.⁵

First, what exactly was tested?

CagriSema is a combination of cagrilintide and semaglutide.¹ Cagrilintide acts at amylin receptors, while semaglutide acts at GLP-1 receptors.¹ REDEFINE 1 tested the combination in adults without diabetes.⁵ Participants had obesity, or overweight plus at least one related complication.⁵ Everyone also received a lifestyle intervention.⁵

The trial was multicentre, double-blind, randomized, and lasted 68 weeks.⁵ It included 3,417 people across four groups.⁵ Of these, 2,108 received the combination, 302 semaglutide, 302 cagrilintide, and 705 placebo.⁵ That design makes the placebo comparison stronger than a before-and-after story.⁵ Still, its result belongs to the people, conditions, and time frame studied.⁵

Randomization matters because it helps balance measured and unmeasured participant differences between groups.⁵ Blinding also reduces the chance that expectations shape how outcomes are assessed.⁵ Neither feature makes a trial universal, but together they make the within-trial comparison more credible than anecdotes, uncontrolled observations, or comparisons assembled from separate populations.⁵

Cagrilintide is named here as a neutral catalog reference connected to one component of the studied combination.¹

The headline result was large

At week 68, estimated average weight change was -20.4% with CagriSema and -3.0% with placebo.² The estimated difference was -17.3 percentage points, with a narrow 95% confidence interval.² This was a treatment-policy analysis, aligned with the intention-to-treat principle.²

That figure describes the average difference between randomized groups.² It does not predict one person’s outcome.² Some participants changed more, while others changed less.⁶ The combination group also reached several prespecified thresholds more often than placebo.⁶ Those included changes of at least 5%, 20%, 25%, and 30%.⁶

The cleanest conclusion is therefore specific.² Under REDEFINE 1 conditions, the combination produced substantially greater average weight reduction than placebo over 68 weeks.² The data do not turn that mean into a certain personal result.²

The analysis method is also part of the interpretation.² A treatment-policy estimate asks about outcomes after assignment regardless of whether participants stopped or changed trial treatment.² That framing preserves the value of randomization and answers a group-level policy question.² It still cannot tell an individual reader exactly what would happen outside the study.²

Better than placebo is not the whole comparison

REDEFINE 1 included semaglutide-only and cagrilintide-only groups.⁵ Its coprimary endpoints tested CagriSema against placebo.² The strongest headline proof is therefore the randomized placebo comparison, not a universal league table.²

Later evidence helps but needs careful labels.⁷ A systematic review pooled three randomized trials with 3,545 participants.⁷ It estimated greater percentage and absolute weight reduction with CagriSema than semaglutide.⁷ Yet pooling does not erase differences among trials.⁷ It combines their assumptions, populations, and weaknesses.⁷

Another analysis compared many interventions through a network of trials.⁴ Its authors explicitly noted that no direct study compared every included intervention head to head.⁴ Such rankings are informative, but they remain indirect.⁴ They cannot prove how every option would perform in one shared trial population.⁴

This distinction is easy to lose when results are reduced to a ranked list.⁴ Direct randomization keeps the compared groups inside one protocol, while a network comparison links results across protocols.⁴ Differences in eligibility, follow-up, background care, and outcome handling can therefore influence an indirect estimate even when the statistical model is carefully constructed.⁴

The safety result belongs beside the headline

Gastrointestinal adverse events affected 79.6% of CagriSema participants and 39.9% of placebo participants.³ Reported events included nausea, vomiting, diarrhea, constipation, and abdominal pain.³ Most were temporary and mild to moderate.³

“Mostly mild to moderate” should not be read as “nothing happened.”³ The proportion experiencing these events was about twice as high with the combination.³ Tolerability is part of the result, not a footnote to it.³ The trial also lasted 68 weeks, so it cannot settle effects beyond that observed period.³

A later meta-analysis versus semaglutide found more nausea and administration-site conditions with the combination.⁷ That synthesis also found broadly comparable overall and serious adverse events between those groups.⁷ These pooled findings are useful context, but they are not unlimited reassurance.⁷

Safety percentages also need their proper denominator and comparator.³ The 79.6% figure means that at least one gastrointestinal event was recorded for that share of combination participants; it does not say that every event had the same type, duration, or severity.³ Reporting both frequency and typical severity gives a more complete reading than either fact alone.³

Blood pressure improved, but outcomes remain unproven

A secondary and post hoc REDEFINE 1 analysis examined blood pressure.⁸ Average systolic pressure changed by -10.9 mm Hg with CagriSema and -2.8 mm Hg with placebo.⁸ Average diastolic changes were -5.4 and -1.7 mm Hg, respectively.⁸ More combination participants reached the analysis’s pressure targets at week 68.⁸

These are measurements and target attainment, not clinical-event outcomes.⁸ The analysis did not establish fewer heart attacks, strokes, or deaths.⁸ That distinction matters whenever a risk marker improves.⁸

The resistant-hypertension subgroup also requires restraint.⁹ It included 167 people, and its confidence interval crossed no difference.⁹ The estimate may be encouraging, but it was imprecise.⁹ A small post hoc subgroup cannot carry the certainty of the full randomized comparison.⁹

Semaglutide is named here as a neutral catalog reference for the other component of CagriSema.¹

What the East Asian study adds

REDEFINE 5 offers a closer regional context than the global REDEFINE 1 population.¹⁰ It randomized 331 adults at 21 Japanese sites and one Taiwanese site.¹⁰ Participants had overweight or obesity under study-specific criteria, and some had type 2 diabetes.¹⁰

After 68 weeks, estimated average weight change was -18.4% with the combination and -11.9% with semaglutide.¹⁰ The estimated between-group difference was -6.5 percentage points.¹⁰ Gastrointestinal disorders occurred in 53% and 51% of participants, respectively.¹⁰

This direct comparison supports an advantage over semaglutide in that enrolled East Asian population.¹⁰ It does not automatically become a Filipino population estimate.¹⁰ Japan supplied nearly all study sites, while Taiwan supplied one.¹⁰ Representation from East Asia improves relevance, but nationality, care settings, and eligibility still matter.¹⁰

REDEFINE 5 answers a different question from REDEFINE 1.¹⁰ Its active comparator helps readers assess the combination against semaglutide within one randomized protocol, whereas REDEFINE 1’s central headline came from the placebo comparison.² Reading the studies together is useful only if their populations, comparators, and stated limits remain visible.¹⁰

What REDEFINE did not prove

REDEFINE 1 enrolled adults under defined criteria and observed them for 68 weeks.⁵ That period cannot establish lifetime outcomes.³ Its blood-pressure analysis did not demonstrate fewer cardiovascular events.⁸ None of those limits cancels the trial’s weight finding.² They define its proper boundary.²

The trial also did not directly settle every comparison readers may care about.⁴ Network estimates connect separate trials, rather than randomizing all choices together.⁴ A registered study is designed to compare CagriSema directly with tirzepatide in adults with obesity.¹¹ A registry description is a plan, not a result.¹¹

Finally, Novo Nordisk funded REDEFINE 1.¹² Funding deserves disclosure because it helps readers judge the research setting.¹² It does not automatically validate or invalidate the methods or findings.¹²

Bottom line

REDEFINE 1 reported a substantial average weight difference between CagriSema and placebo over 68 weeks.² It also documented frequent gastrointestinal effects, mostly temporary and mild to moderate.³ A later analysis found larger blood-pressure changes, but not fewer cardiovascular events.⁸

For Filipino readers, the disciplined reading is neither hype nor dismissal.² The result is strong within its randomized trial boundaries.⁵ Evidence from Japan and Taiwan adds an important direct semaglutide comparison, but not a Filipino-specific estimate.¹⁰ Longer observation, broader representation, and completed direct comparisons can answer different questions.¹¹ Until then, averages, subgroups, and indirect rankings should remain clearly separated.⁹

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Frequently asked questions

What is CagriSema?

CagriSema combines two researched agents: cagrilintide and semaglutide.¹ The first acts at amylin receptors, while the second acts at GLP-1 receptors.¹ REDEFINE 1 studied their combination in adults without diabetes who met defined weight and health criteria.⁵

How much average weight change occurred in REDEFINE 1?

At 68 weeks, estimated average change was -20.4% with CagriSema and -3.0% with placebo.² The estimated between-group difference was -17.3 percentage points.² These are trial-group averages, not a promise about any individual response.²

Did everyone in the combination group reach the headline number?

No group average describes every participant.² REDEFINE 1 separately reported that more combination participants reached several weight-change thresholds than placebo participants.⁶ That distribution shows varied responses among participants, even when the average comparison was large.⁶

Was CagriSema proven better than semaglutide?

REDEFINE 5 directly found greater average weight reduction with the combination than semaglutide in its Japanese and Taiwanese population.¹⁰ A three-trial meta-analysis pointed the same way.⁷ Neither result proves identical effects for every population or setting.¹⁰

What were the main adverse events?

Gastrointestinal events were the prominent safety finding in REDEFINE 1.³ They affected 79.6% with CagriSema and 39.9% with placebo.³ Nausea, vomiting, diarrhea, constipation, and abdominal pain were reported, mainly as temporary mild-to-moderate events.³

Did the blood-pressure findings prove heart protection?

No.⁸ The analysis found larger average blood-pressure reductions and greater target attainment with CagriSema than placebo.⁸ It did not demonstrate fewer heart attacks, strokes, or deaths.⁸ A changed risk marker and a changed clinical outcome are different claims.⁸

Why mention future direct comparisons?

Indirect networks can compare interventions that never met within one randomized trial.⁴ Their rankings depend on connections across separate studies.⁴ A registered direct comparison may answer that narrower question, but its registry entry is only a study plan and contains no outcome findings.¹¹

Sources

Footnotes

1. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.. Human phase 3 background describing the combination. A description of the components does not establish clinical benefit. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

2. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.. Human REDEFINE 1 treatment-policy analysis. This is a group average from a controlled trial, not an individual forecast. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸ ↩¹⁹ ↩²⁰ ↩²¹ ↩²² ↩²³ ↩²⁴

3. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.. Human REDEFINE 1 safety analysis. The events were mainly transient and mild to moderate, but 68 weeks cannot settle longer-term safety. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶

4. Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.. Indirect comparison across 25 human randomized trials. Rankings from indirect comparisons are not equivalent to a single direct randomized comparison. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹²

5. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.. Human, 68-week, multicentre, randomized phase 3a trial with lifestyle intervention in every group. The eligibility criteria limit generalization beyond the enrolled population. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷

6. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.. Human REDEFINE 1 confirmatory secondary endpoints. Threshold results do not describe every participant's response. ↩ ↩² ↩³ ↩⁴ ↩⁵

7. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.. Systematic review and meta-analysis of human randomized trials. A pooled estimate inherits differences and limitations across included trials. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

8. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.. Human secondary and post hoc analysis of REDEFINE 1. This analysis does not prove fewer heart attacks, strokes, or deaths. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³

9. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.. Post hoc human subgroup of 167 REDEFINE 1 participants. The subgroup was small and not definitive. ↩ ↩² ↩³ ↩⁴ ↩⁵

10. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.. Human, randomized, active-controlled, 68-week East Asian phase 3a trial. The study population and entry criteria were specific, and only one site was in Taiwan. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵

11. Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity. Human clinical-trial registry record describing an ongoing comparative study. A study plan provides no outcome results. ↩ ↩² ↩³ ↩⁴

12. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.. Funding disclosure for the human phase 3a trial. Funding is relevant context but does not by itself determine whether findings are valid. ↩ ↩² ↩³